{"id":"venlafaxine-effexor","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Nausea"},{"rate":"20-30","effect":"Headache"},{"rate":"15-20","effect":"Dizziness"},{"rate":"15-20","effect":"Insomnia"},{"rate":"10-15","effect":"Somnolence"},{"rate":"10-15","effect":"Sweating"},{"rate":"10-15","effect":"Sexual dysfunction"},{"rate":"5-10","effect":"Hypertension"},{"rate":"5-10","effect":"Weight gain"},{"rate":"variable","effect":"Withdrawal symptoms upon discontinuation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks the reuptake transporters for both serotonin and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. At higher doses, it also has weak dopamine reuptake inhibition. This mechanism is thought to restore balance in neurotransmitter signaling and alleviate symptoms of depression and anxiety disorders.","oneSentence":"Venlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:07.878Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Social anxiety disorder"},{"name":"Panic disorder"},{"name":"Vasomotor symptoms associated with menopause"}]},"trialDetails":[{"nctId":"NCT07497282","phase":"PHASE2","title":"Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2026-03-26","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT07361796","phase":"NA","title":"The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12-15","conditions":"Herpes Zoster, Pain, Postherpetic Neuralgia","enrollment":832},{"nctId":"NCT06049797","phase":"","title":"A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2023-11-15","conditions":"Hot Flashes","enrollment":999},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT07230171","phase":"NA","title":"The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-09-15","conditions":"Fibromyalgia, Pregabalin, Esketamine","enrollment":106},{"nctId":"NCT07361809","phase":"NA","title":"The Analgesic Efficacy and Safety of Desvenlafaxine in Patients With Herpes Zoster","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12-15","conditions":"Herpes Zoster, Pain","enrollment":750},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT07359248","phase":"NA","title":"Desvenlafaxine for Preventive Treatment of Frequent Episodic Tension-type Headache","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-01","conditions":"Tension Type Headache","enrollment":432},{"nctId":"NCT04747314","phase":"PHASE2, PHASE3","title":"Treating Negative Affect in Low Back Pain Patients","status":"COMPLETED","sponsor":"Ajay Wasan, MD, Msc","startDate":"2021-03-31","conditions":"Chronic Low Back Pain, Negative Affectivity","enrollment":308},{"nctId":"NCT07186751","phase":"NA","title":"The Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-09-20","conditions":"Fibromyalgia, Pregabalin, Venlafaxine","enrollment":750},{"nctId":"NCT06659094","phase":"NA","title":"Reducing Maximal Support in OCD: Efficacy of Stepped-Care Online CBT","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2023-08-21","conditions":"Obsessive Compulsive Disorder (OCD)","enrollment":95},{"nctId":"NCT07328373","phase":"","title":"Neurobiological and Genomic Predictors of Relapse in Depression","status":"RECRUITING","sponsor":"Mehmet Kemal Arikan","startDate":"2025-01-01","conditions":"Healthy, Major Depressive Disorder (MDD)","enrollment":204},{"nctId":"NCT07330648","phase":"PHASE2","title":"Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder","status":"RECRUITING","sponsor":"Anhui Medical University","startDate":"2025-10-10","conditions":"Generalized Anxiety Disorder","enrollment":216},{"nctId":"NCT04961190","phase":"PHASE4","title":"A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-05-25","conditions":"Posttraumatic Stress Disorder","enrollment":302},{"nctId":"NCT06965569","phase":"PHASE1","title":"Multiple Ascending Dose Phase 1 Study of ALA-3000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2025-04-21","conditions":"Treatment Resistant Depression","enrollment":37},{"nctId":"NCT00792168","phase":"PHASE4","title":"Physiologic Monitoring of Antidepressant Response","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"1996-11","conditions":"Major Depression","enrollment":38},{"nctId":"NCT06295562","phase":"PHASE4","title":"Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2024-11-05","conditions":"Obstructive Sleep Apnea of Adult","enrollment":45},{"nctId":"NCT05973786","phase":"PHASE3","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-02-11","conditions":"Bipolar Depression","enrollment":418},{"nctId":"NCT06803485","phase":"PHASE4","title":"Effect of Venlafaxine Versus Dosulepin in Pain Predominant Somatic Symptom Disorder","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2025-03-11","conditions":"Somatic Symptom Disorder (DSM-V)","enrollment":84},{"nctId":"NCT07161492","phase":"NA","title":"A Study on Functional Connectome and rTMS Intervention of Cognitive Flexibility Impairment in Patients With Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2025-09","conditions":"Depressive Disorder, Major, Cognitive Impairment","enrollment":182},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT06508710","phase":"PHASE3","title":"Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-10-20","conditions":"Major Depressive Episode","enrollment":60},{"nctId":"NCT02051413","phase":"PHASE4","title":"Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2014-02-18","conditions":"Major Depressive Disorder, Major Depressive Episode","enrollment":67},{"nctId":"NCT07120880","phase":"PHASE3","title":"Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-09","conditions":"Major Depressive Disorder (MDD) With Insomnia","enrollment":184},{"nctId":"NCT05830279","phase":"","title":"Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2023-05-01","conditions":"Nausea With Vomiting Chemotherapy-Induced, Depression, Reactive, Cancer Pain","enrollment":600},{"nctId":"NCT07025590","phase":"NA","title":"Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-04-22","conditions":"Cardiovascular Diseases (CVD), Depression Anxiety Disorder","enrollment":106},{"nctId":"NCT03532477","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Venlafaxine","status":"RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2016-11-02","conditions":"Obesity, Morbid","enrollment":12},{"nctId":"NCT05023278","phase":"PHASE4","title":"The Use of Venlafaxine in Reducing Pain in Primary Total Knee Replacement","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-05-10","conditions":"Acute Pain, Chronic Pain, Knee Pain Chronic","enrollment":100},{"nctId":"NCT04539951","phase":"PHASE2","title":"Pragmatic Trial of Obsessive-compulsive Disorder","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2020-09-22","conditions":"Obsessive-Compulsive Disorder","enrollment":1600},{"nctId":"NCT04973930","phase":"PHASE3","title":"Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer","status":"SUSPENDED","sponsor":"New York State Psychiatric Institute","startDate":"2022-03-01","conditions":"Major Depressive Disorder, Breast Cancer, Venlafaxine","enrollment":20},{"nctId":"NCT04597190","phase":"PHASE4","title":"Sequenced Treatment Effectiveness for Posttraumatic Stress","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-06-01","conditions":"PTSD","enrollment":700},{"nctId":"NCT01114698","phase":"PHASE2","title":"A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-03","conditions":"Depression","enrollment":12},{"nctId":"NCT02417064","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-10","conditions":"Treatment-resistant Depression","enrollment":346},{"nctId":"NCT03434041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-25","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":252},{"nctId":"NCT02493868","phase":"PHASE3","title":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":719},{"nctId":"NCT02418585","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-07","conditions":"Treatment-resistant Depression","enrollment":236},{"nctId":"NCT02497287","phase":"PHASE3","title":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-30","conditions":"Treatment-resistant Depression","enrollment":802},{"nctId":"NCT02422186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-20","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":139},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT06278038","phase":"NA","title":"Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-02-22","conditions":"Major Depression Disorder","enrollment":84},{"nctId":"NCT00667121","phase":"","title":"Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2011-03-16","conditions":"Breast Cancer, Depression, Hot Flashes","enrollment":88},{"nctId":"NCT06106529","phase":"PHASE3","title":"REDucing Hot FLASHes in Women Using Endocrine Therapy.","status":"RECRUITING","sponsor":"Reinier de Graaf Groep","startDate":"2024-10-03","conditions":"Breast Cancer, Hot Flash Due to Medication","enrollment":260},{"nctId":"NCT04977271","phase":"PHASE4","title":"Mood Disorders in Head and Neck Cancer Patients","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2024-01-05","conditions":"Depressive Disorder, Head and Neck Cancer","enrollment":""},{"nctId":"NCT01000623","phase":"NA","title":"Venlafaxine and Hypnosis or Focused Attention in Treating Patients with Hot Flashes","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2010-01-31","conditions":"Hot Flashes","enrollment":71},{"nctId":"NCT04446039","phase":"","title":"Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-07-04","conditions":"Major Depression","enrollment":370212},{"nctId":"NCT00834964","phase":"PHASE1","title":"Venlafaxine 25 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-12","conditions":"Healthy","enrollment":30},{"nctId":"NCT00834249","phase":"PHASE1","title":"Venlafaxine 25 mg Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-12","conditions":"Healthy","enrollment":18},{"nctId":"NCT00200902","phase":"PHASE4","title":"Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2005-08","conditions":"Depression","enrollment":88},{"nctId":"NCT04218123","phase":"PHASE2, PHASE3","title":"Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2020-02-05","conditions":"Meniere Disease","enrollment":40},{"nctId":"NCT04639193","phase":"PHASE2","title":"Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-12-01","conditions":"OSA, Obstructive Sleep Apnea","enrollment":20},{"nctId":"NCT04478526","phase":"NA","title":"Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions","status":"COMPLETED","sponsor":"Dr. Nazanin Alavi","startDate":"2020-04-29","conditions":"Generalized Anxiety Disorder","enrollment":115},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT05724849","phase":"PHASE2","title":"Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2023-08-01","conditions":"Head and Neck Cancer, Depression","enrollment":""},{"nctId":"NCT06131268","phase":"PHASE4","title":"The Role of Negr1 In Modulating Neuroplasticity in Major Depression (RONIN)","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2022-03-01","conditions":"Major Depressive Disorder, Bipolar Affective Disorder, Currently Depressed, Moderate","enrollment":30},{"nctId":"NCT04437485","phase":"PHASE2","title":"eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk","status":"COMPLETED","sponsor":"Indiana University","startDate":"2020-10-14","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":46},{"nctId":"NCT03538691","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-07-13","conditions":"Major Depressive Disorder","enrollment":1149},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT05931965","phase":"NA","title":"Combination Therapy of Different Antidepressants With Dietary Supplements","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2022-10-05","conditions":"Depression","enrollment":88},{"nctId":"NCT05952713","phase":"","title":"Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder","status":"COMPLETED","sponsor":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","startDate":"2022-10-01","conditions":"Major Depressive Disorder","enrollment":73336},{"nctId":"NCT02058693","phase":"PHASE4","title":"Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":41},{"nctId":"NCT05884268","phase":"PHASE1, PHASE2","title":"Venlafaxine for Postoperative Pain of Laparoscopic Cholecystectomy","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2023-05-30","conditions":"Laparoscopic Cholecystectomy","enrollment":60},{"nctId":"NCT05875610","phase":"PHASE4","title":"Preventive Approach Using Venlafaxine","status":"UNKNOWN","sponsor":"Mit Ghamr Oncology Center","startDate":"2023-05-01","conditions":"Peripheral Neuropathy Due to Chemotherapy","enrollment":60},{"nctId":"NCT02958527","phase":"","title":"Drug Use Investigation Of Effexor (SECONDARY DATA COLLECTION STUDY; SAFETY AND EFFICACY OF EFFEXOR.UNDER JAPANESE MEDICAL PRACTICE)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2016-10-03","conditions":"Depression/Depressed State","enrollment":1408},{"nctId":"NCT04653337","phase":"PHASE2","title":"Neuroimaging Guided and Robot-assisted rTMS for Suicidal Ideation of Depression","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2020-09-28","conditions":"Suicidal Ideation, Depression","enrollment":56},{"nctId":"NCT04748276","phase":"","title":"Tracking Response to Antidepressants in Advance of Investigational Trials","status":"UNKNOWN","sponsor":"Adams Clinical","startDate":"2019-01-02","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT05777876","phase":"NA","title":"Early Identification of TRD and Construction and Clinical Validation of NTBS Precision Technology","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2023-01-01","conditions":"Treatment-Resistant Depression","enrollment":400},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT05569031","phase":"PHASE4","title":"Treatment of Withdrawal Symptoms and Prevention of Relapse in Patients With Tramadol Abuse","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2019-01-01","conditions":"Opiate Withdrawal Syndrome","enrollment":52},{"nctId":"NCT01962753","phase":"NA","title":"Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2012-05-10","conditions":"Elderly, Major Depression","enrollment":92},{"nctId":"NCT05280015","phase":"PHASE2","title":"Microbiotherapy in Characterized Depressive Disorder","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-06-08","conditions":"Depression, Depressive Disorder, Depressive Disorder, Major","enrollment":92},{"nctId":"NCT02977299","phase":"PHASE4","title":"Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-05-01","conditions":"Treatment Resistant Major Depressive Disorder","enrollment":278},{"nctId":"NCT04965272","phase":"PHASE2","title":"A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2021-08-18","conditions":"Generalized Anxiety Disorder","enrollment":""},{"nctId":"NCT03574792","phase":"NA","title":"Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2018-05-03","conditions":"Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","enrollment":62},{"nctId":"NCT05104918","phase":"PHASE3","title":"Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities","status":"UNKNOWN","sponsor":"Scotmann Pharmaceuticals","startDate":"2022-02","conditions":"Major Depressive Disorder","enrollment":500},{"nctId":"NCT03588572","phase":"NA","title":"The Effect of Venlafaxine on Language Function in Patients With Subcortical Aphasia: A fMRI Study","status":"COMPLETED","sponsor":"Guangzhou General Hospital of Guangzhou Military Command","startDate":"2018-08-01","conditions":"Subcortical Aphasia, Ischemic Stroke","enrollment":43},{"nctId":"NCT00354432","phase":"PHASE3","title":"Soy Protein/Effexor Hormone Therapy for Prostate Cancer","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2007-02-01","conditions":"Hot Flashes, Prostate Cancer","enrollment":120},{"nctId":"NCT03294525","phase":"","title":"Towards Neurobiology-based Diagnosis and Treatment of Affective Disorders","status":"UNKNOWN","sponsor":"Peking University","startDate":"2016-01","conditions":"Affective Disorder","enrollment":400},{"nctId":"NCT00878748","phase":"PHASE4","title":"Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder","status":"WITHDRAWN","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-04","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT02655354","phase":"NA","title":"A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-10","conditions":"Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders","enrollment":635},{"nctId":"NCT01235338","phase":"PHASE1","title":"Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2010-10-28","conditions":"Healthy","enrollment":80},{"nctId":"NCT01436175","phase":"PHASE3","title":"SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study","status":"TERMINATED","sponsor":"Shire","startDate":"2012-02-27","conditions":"Major Depressive Disorder","enrollment":1570},{"nctId":"NCT01436162","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-19","conditions":"Major Depressive Disorder","enrollment":1105},{"nctId":"NCT01436149","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-27","conditions":"Major Depressive Disorder","enrollment":1262},{"nctId":"NCT00564278","phase":"NA","title":"Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-02","conditions":"Depression","enrollment":217},{"nctId":"NCT04396314","phase":"NA","title":"Effectiveness of Basic Body Awareness Therapy in Post-traumatic Stress Disorders: A Randomized Clinical Trial","status":"UNKNOWN","sponsor":"Universitat de Lleida","startDate":"2021-09-01","conditions":"PostTraumatic Stress Disorder","enrollment":54},{"nctId":"NCT04806230","phase":"","title":"Serum Concentrations of Antidepressant Drugs in Pregnant Women - a Naturalistic Study","status":"COMPLETED","sponsor":"Linkoeping University","startDate":"2011-04-01","conditions":"Pharmacokinetics, Antidepressive Agents, Pregnancy","enrollment":81},{"nctId":"NCT04737967","phase":"PHASE2, PHASE3","title":"The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Mendel AI","startDate":"2021-02-15","conditions":"Oncology Pain, Chemotherapy-induced Peripheral Neuropathy","enrollment":60},{"nctId":"NCT01485887","phase":"PHASE3","title":"Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2012-01","conditions":"Major Depressive Disorder","enrollment":50},{"nctId":"NCT01441440","phase":"PHASE3","title":"Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-11","conditions":"Major Depressive Disorder","enrollment":538},{"nctId":"NCT00644982","phase":"PHASE4","title":"A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2002-10","conditions":"Depressive Disorder, Major","enrollment":163},{"nctId":"NCT02637193","phase":"PHASE1","title":"A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2015-12","conditions":"Healthy Subjects","enrollment":54},{"nctId":"NCT00151450","phase":"PHASE3","title":"Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-03","conditions":"Anxiety","enrollment":390},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT02955719","phase":"NA","title":"CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In Dementia","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2016-03-30","conditions":"Depression, Anxiety, Mild Cognitive Impairment","enrollment":145},{"nctId":"NCT00150839","phase":"PHASE4","title":"Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2006-03","conditions":"Depressive Disorder, Major","enrollment":80},{"nctId":"NCT04664088","phase":"NA","title":"Acupuncture for Prophylaxis of Vestibular Migraine","status":"UNKNOWN","sponsor":"Affiliated Hospital of Jiaxing University","startDate":"2021-01-01","conditions":"Vestibular Migraine","enrollment":72},{"nctId":"NCT02755194","phase":"","title":"\"Drugs in Lactation\" Analysis Consortium","status":"TERMINATED","sponsor":"The Hospital for Sick Children","startDate":"2014-09","conditions":"Lactation","enrollment":68},{"nctId":"NCT03464383","phase":"PHASE4","title":"Anxiety and Depression in Epilepsy: A Treatment Study","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-05-07","conditions":"Anxiety, Depression, Epilepsy","enrollment":69},{"nctId":"NCT00080158","phase":"PHASE2, PHASE3","title":"Treatment of Adolescent Suicide Attempters (TASA)","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2004-03","conditions":"Depression, Suicide, Attempted","enrollment":120},{"nctId":"NCT03274817","phase":"PHASE1","title":"A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2009-06-18","conditions":"Alzheimer Disease","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"venlafaxine (Effexor)","genericName":"venlafaxine (Effexor)","companyName":"National Institute of Mental Health (NIMH)","companyId":"national-institute-of-mental-health-nimh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Venlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites. Used for Major depressive disorder, Generalized anxiety disorder, Social anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}